Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02757885 · ClinicalTrials.gov registry record · Phase 2
Transplantation for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow
A Phase 2 study of Sickle Cell Disease, sponsored by Emory University.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT02757885 is a Phase 2 study of Sickle Cell Disease that has completed, run by Emory University. The registered enrollment target is 10 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02757885, a Phase 2 study of Sickle Cell Disease, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn if it is possible and safe to treat persons with severe sickle cell disease (SCD) by bone marrow transplant (BMT) from human leukocyte antigen (HLA) half-matched related donors. Preparation before transplant includes the chemotherapy drugs hydroxyurea, fludarabine, thiotepa, anti-thymocyte globulin, and cyclophosphamide. It also includes radiation.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Hydroxyurea
- DRUG Thiotepa
- PROCEDURE Bone Marrow Transplant (BMT)
- DRUG Fludarabine monophosphate
Study Locations (1)
Georgia
- Children's Healthcare of Atlanta - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-07-10 |
| Est. Completion | 2021-12-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02757885
The ClinicalTrials.gov registry entry for NCT02757885 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (97% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT02757885 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT02757885 about?
NCT02757885 is a clinical study titled "Transplantation for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow". The purpose of this study is to learn if it is possible and safe to treat persons with severe sickle cell disease (SCD) by bone marrow transplant (BMT) from human leukocyte antigen (HLA) half-matched related donors. Preparation before transplant includes the chemotherapy drugs hydroxyurea, fludarabi...
What is the current status of trial NCT02757885?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2019-07-10. Estimated completion is 2021-12-14.
What conditions does trial NCT02757885 study?
This clinical trial studies the following conditions: Sickle Cell Disease.
What interventions are being tested in trial NCT02757885?
The interventions under investigation include: Cyclophosphamide (DRUG), Hydroxyurea (DRUG), Thiotepa (DRUG), Bone Marrow Transplant (BMT) (PROCEDURE), Fludarabine monophosphate (DRUG).
Who is sponsoring clinical trial NCT02757885?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02757885 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET
RECRUITING · Phase 2
-
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
RECRUITING · Phase 2
-
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
RECRUITING · Phase 2
-
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
RECRUITING · Phase 2
-
Allo HSCT for High Risk Hemoglobinopathies
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.